RA Capital Healthcare Fund LP's Form 4 filing
Sionna Therapeutics, Inc. (SION) · filed Feb 10, 2025
- Accession no.
- 0001415889-25-003504
- Filed
- Feb 10, 2025, 5:04 PM ET
- Trade date
- Feb 10, 2025
- Filing delay
- Same day
- Rule 10b5-1 plan
- Not checked
This filing lists 6 non-derivative transactions and 10 derivative transactions. Open-market purchases total $20.3M. It was filed on the trade date.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| RA Capital Healthcare Fund LPCIK 0001315082 | Director, 10% Owner |
| Ra Capital Management, L.P.CIK 0001346824 | Director, 10% Owner |
| Kolchinsky PeterCIK 0001384859 | Director, 10% Owner |
| Shah Rajeev M.CIK 0001619841 | Director, 10% Owner |
| RA Capital Nexus Fund, L.P.CIK 0001780117 | Director |
| RA Capital Nexus Fund III, L.P.CIK 0001883840 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 10, 2025 | Common Stock | CConversionAcquired | +5,021,990 | –F1 | – | 5,900,779 | Indirect | |
| Feb 10, 2025 | Common Stock | CConversionAcquired | +527,444 | –F1 | – | 869,651 | Indirect | |
| Feb 10, 2025 | Common Stock | CConversionAcquired | +2,222,084 | –F1 | – | 2,222,084 | Indirect | |
| Feb 10, 2025 | Common Stock | CConversionAcquired | +179,975 | –F1 | – | 327,808 | Indirect | |
| Feb 10, 2025 | Common Stock | PPurchaseAcquired | +1,022,586 | $18.00 | +$18,406,548 | 6,923,365 | Indirect | |
| Feb 10, 2025 | Common Stock | PPurchaseAcquired | +102,414 | $18.00 | +$1,843,452 | 2,324,498 | Indirect |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 10, 2025 | Common Stock | CConversionDisposed | −560,642 | $0.00 | $0 | 0 | Indirect | |
| Feb 10, 2025 | Common Stock | CConversionDisposed | −218,375 | $0.00 | $0 | 0 | Indirect | |
| Feb 10, 2025 | Common Stock | CConversionDisposed | −94,486 | $0.00 | $0 | 0 | Indirect | |
| Feb 10, 2025 | Common Stock | CConversionDisposed | −841,716 | $0.00 | $0 | 0 | Indirect | |
| Feb 10, 2025 | Common Stock | CConversionDisposed | −309,069 | $0.00 | $0 | 0 | Indirect | |
| Feb 10, 2025 | Common Stock | CConversionDisposed | −85,489 | $0.00 | $0 | 0 | Indirect | |
| Feb 10, 2025 | Common Stock | CConversionDisposed | −632,244 | $0.00 | $0 | 0 | Indirect | |
| Feb 10, 2025 | Common Stock | CConversionDisposed | −1,475,237 | $0.00 | $0 | 0 | Indirect | |
| Feb 10, 2025 | Common Stock | CConversionDisposed | −2,987,388 | $0.00 | $0 | 0 | Indirect | |
| Feb 10, 2025 | Common Stock | CConversionDisposed | −746,847 | $0.00 | $0 | 0 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock (collectively the "Preferred Stock") converted into shares of Common Stock of the Issuer on a one-for-1.4611 basis upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date.
Referenced by the price of 4 transactions in Table I.
Remarks
Joshua Resnick, a Partner of the Adviser, serves on the Issuer's board of directors.